Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey


Creative Commons License

Kilickap S., Demirci U., Bugdayci F., Tural D., Korkmaz T., Paydas S., ...Daha Fazla

JOURNAL OF THORACIC ONCOLOGY, cilt.14, sa.10, 2019 (SCI-Expanded) identifier